Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study

Abstract

Long-term evidence supports a clustering of cardiovascular events in the early morning and smaller mechanistic studies in aspirin-treated patients have shown increased platelet reactivity at the end of the dosing interval. Comparative pharmacodynamic analyses for different adenosine diphosphate (ADP) receptor inhibitors in percutaneous coronary intervention-treated acute coronary syndrome (ACS) patients are lacking and this pre-specified analysis from the randomized Testing Responsiveness To Platelet Inhibition On Chronic Antiplatelet Treatment For Acute Coronary Syndromes (TROPICAL-ACS) trial aimed for the first time at investigating diurnal variability of on-treatment platelet reactivity in clopidogrel versus prasugrel treated patients. TROPICAL-ACS randomized 2,610 ACS patients to either treatment with prasugrel (control group) or to a platelet function testing-guided de-escalation of anti-platelet treatment with a switch to clopidogrel (guided de-escalation group). This study design enabled a diurnal comparison of on-prasugrel versus on-clopidogrel treatment platelet reactivity under steady-state conditions. For 2,526 patients (97%), both the exact time of blood sampling and the ADP-induced platelet aggregation value (in units, Multiplate analyser) were available. Platelet reactivity in patients on clopidogrel (n = 1,265) was higher and subject to significant diurnal variability (p = 0.019) with a peaking of platelet reactivity in the early morning (5–10 a.m.). In prasugrel-treated patients (n = 1,261), there was no sign for diurnal variability (p = 0.174) or a peaking of platelet reactivity in the morning. The potent ADP receptor inhibitor prasugrel is not subject to diurnal variability while we observed a significant diurnal variability of on-clopidogrel platelet reactivity. The clinical impact of this observation may differ for patients with and without an adequate response to clopidogrel treatment and the issue of diurnal variability of platelet reactivity in ACS patients warrants further investigation.

Keywords

acute coronary syndrome - prasugrel - clopidogrel - diurnal variability - circadian variability

Note

This study is registered with ClinicalTrials.gov, number NCT01959451, and EudraCT, 2013–001636–22.

^* M.K.F., R.H.R. and P.M.H. contributed equally to the manuscript, i.e. shared first-authorship.

^** K.H. and D.S. contributed equally to the manuscript, i.e. shared senior-authorship.

• References

• 1 Wiviott SD, Braunwald E, McCabe CH. , et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
• 2 Wallentin L, Becker RC, Budaj A. , et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
• 3 Palmerini T, Della Riva D, Benedetto U. , et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J 2017; 38 (14) 1034-1043
• 4 Muller JE, Ludmer PL, Willich SN. , et al. Circadian variation in the frequency of sudden cardiac death. Circulation 1987; 75 (01) 131-138
• 5 Muller JE, Stone PH, Turi ZG. , et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313 (21) 1315-1322
• 6 Sibbing D, Gross L, Aradi D. Prevention of cardiovascular events with antiplatelet treatment: does time of intake matter for aspirin and ADP receptor blockers?. Thromb Haemost 2016; 115 (01) 3-6
• 7 Mogabgab O, Wiviott SD, Antman EM. , et al. Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. Clin Cardiol 2013; 36 (04) 222-227
• 8 Mahmoud KD, Lennon RJ, Ting HH, Rihal CS, Holmes Jr DR. Circadian variation in coronary stent thrombosis. JACC Cardiovasc Interv 2011; 4 (02) 183-190
• 9 Tofler GH, Brezinski D, Schafer AI. , et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316 (24) 1514-1518
• 10 Neumann FJ, Sousa-Uva M, Ahlsson A. , et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2018 Doi: 10.1093/eurheartj/ehy394
• 11 Valgimigli M, Bueno H, Byrne RA. , et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (03) 213-260
• 12 Freynhofer MK, Bruno V, Wojta J, Huber K. The role of platelets in athero-thrombotic events. Curr Pharm Des 2012; 18 (33) 5197-5214
• 13 Perneby C, Wallén NH, Rooney C, Fitzgerald D, Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95 (04) 652-658
• 14 Henry P, Vermillet A, Boval B. , et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105 (02) 336-344
• 15 Dragani A, Pascale S, Recchiuti A. , et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010; 115 (05) 1054-1061
• 16 Würtz M, Hvas AM, Jensen LO. , et al. 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Int J Cardiol 2014; 175 (02) 274-279
• 17 Kriszbacher I, Ajtay Z, Koppán M, Bódis J. Can the time of taking aspirin influence the frequency of cardiovascular events?. Am J Cardiol 2005; 96 (04) 608-610
• 18 Bonten TN, Saris A, van Oostrom MJ. , et al. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial. Thromb Haemost 2014; 112 (06) 1209-1218
• 19 Kozinski M, Bielis L, Wisniewska-Szmyt J. , et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011; 22 (08) 579-587
• 20 Gruber SC, Freynhofer MK, Willheim M. , et al. Twenty-four-hour time dependency of clopidogrel effects in patients with acute coronary syndromes: the CiCAD-Study. Platelets 2018; 1-7
• 21 Sibbing D, Aradi D, Jacobshagen C. , et al; TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017; 390 (10104): 1747-1757
• 22 Sibbing D, Gross L, Trenk D. , et al; TROPICAL-ACS Investigators. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial. Eur Heart J 2018; 39 (29) 2749-2758
• 23 Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999; 25 (Suppl. 02) 15-19
• 24 Aradi D, Kirtane A, Bonello L. , et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 36 (27) 1762-1771
• 25 Tantry US, Bonello L, Aradi D. , et al; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62 (24) 2261-2273
• 26 Dunn OJ. Multiple comparisons using rank sums. Technometrics 1964; 6 (03) 241-252
• 27 Scheer FA, Michelson AD, Frelinger III AL. , et al. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors. PLoS One 2011; 6 (09) e24549
• 28 Sibbing D, Morath T, Braun S. , et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103 (01) 151-159
• 29 Sibbing D, Braun S, Morath T. , et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53 (10) 849-856
• 30 Sibbing D, Braun S, Jawansky S. , et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99 (01) 121-126
• 31 Järemo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252 (03) 233-238
• 32 Yukhanyan L, Freynhofer MK, Siller-Matula J, Schrör K, Huber K. Genetic variability in response to clopidogrel therapy and its clinical implications. Thromb Haemost 2011; 105 (Suppl. 01) S55-S59
• 33 Tentzeris I, Siller-Matula J, Farhan S, Jarai R, Wojta J, Huber K. Platelet function variability and non-genetic causes. Thromb Haemost 2011; 105 (Suppl. 01) S60-S66
• 34 Freynhofer MK, Bruno V, Brozovic I. , et al. Is increased platelet turnover responsible for low responsiveness to different thienopyridienes? A case report of recurrent stent thromboses. Thromb Haemost 2011; 106 (01) 182-184
• 35 Freynhofer MK, Brozovic I, Bruno V. , et al. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. Thromb Haemost 2011; 106 (02) 230-239
• 36 Jakubowski JA, Payne CD, Li YG. , et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008; 99 (01) 215-222
• 37 Angiolillo DJ, Saucedo JF, Deraad R. , et al; SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 2010; 56 (13) 1017-1023
• 38 Mogabgab O, Wiviott SD, Cannon CP. , et al. Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. J Cardiovasc Pharmacol Ther 2013; 18 (06) 555-559
• 39 Suárez-Barrientos A, López-Romero P, Vivas D. , et al. Circadian variations of infarct size in acute myocardial infarction. Heart 2011; 97 (12) 970-976